The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
Open accessAbstract
Purpose: Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. Patients and Methods: Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. Results: IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. Conclusion: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationHarrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationHarrell (2015) · Springer Series in Statistics · doi:10.1007/978-3-319-19425-7 · Cited by 6,878
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Self-citationCairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Self-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Self-citationAltered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
Smith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
Self-citationCairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
Self-citation(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 604
REIFENBERGER, J., Reifenberger, G., Liu, L., James, C. D., Wechsler, W., & Collins, V. P. (1994) · PubMed Central · Cited by 601
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 529
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
Cairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T., Buckner, J., Fulton, D., Dropcho, E., Stewart, D., & Schold, C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2013 · Cited by 442
Self-citationReversal of DNA alkylation damage by two human dioxygenases
Duncan, T., Trewick, S. C., Koivisto, P., Bates, P. A., Lindahl, T., & Sedgwick, B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262589799 · Cited by 413
Ghosh, M., Casella, G., & Berger, R. L. (1994) · Journal of the American Statistical Association · doi:10.2307/2290879 · Cited by 411
van den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. A., Taphoorn, M. J. B., Wesseling, P., Frenay, M., Tijssen, C. C., Lacombe, D., Idbaih, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2902 · Cited by 381
Hoang-Xuan, K., Capelle, L., Kujas, M., Taillibert, S., Duffau, H., Lejeune, J., Polivka, M., Crinière, E., Marie, Y., Mokhtari, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.169 · Cited by 356
Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 344
Self-citationYip, S., Butterfield, Y. S., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., Birol, I., Chesnelong, C., Chiu, R., Chuah, E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.2995 · Cited by 307
Self-citationvan den Bent, M. J., Taphoorn, M. J. B., Brandes, A. A., Menten, J., Stupp, R., Frenay, M., Chinot, O., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.015 · Cited by 297
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20575 · Cited by 278
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M. R., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq497 · Cited by 255
van den Bent, M. J., Kros, J. M., Heimans, J. J., Pronk, L. C., van Groeningen, C. J., Krouwer, H. G. J., Taphoorn, M. J. B., Zonnenberg, B. A., Tijssen, C. C., Twijnstra, A., et al. (1998) · Neurology · doi:10.1212/wnl.51.4.1140 · Cited by 206
Chinot, O.-L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.-M., & Grisoli, F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2449 · Cited by 179
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
Ducray, F., Idbaih, A., de Reyniès, A., Bièche, I., Thillet, J., Mokhtari, K., Lair, S., Marie, Y., Paris, S., Vidaud, M., et al. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-41 · Cited by 173
Cooper, L., Gutman, D. A., Long, Q., Johnson, B. A., Cholleti, S. R., Kurç, T., Saltz, J. H., Brat, D. J., & Moreno, C. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012548 · Cited by 152
Jenkins, R. B., Xiao, Y., Sicotte, H., Decker, P. A., Kollmeyer, T. M., Hansen, H. M., Kosel, M., Zheng, S., Walsh, K. M., Rice, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2388 · Cited by 152
Self-citationLevin, V. A., Edwards, M. S. B., Wright, D., Seager, M. L., Tp, S., Jj, T., & Wilson, C. B. (1980) · PubMed · Cited by 141
Kim, L., Hochberg, F. H., Thornton, A. F., et al. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.85.4.0602 · Cited by 139
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma
Macdonald, D., Gaspar, L. E., & Cairncross, J. G. (1990) · Annals of Neurology · doi:10.1002/ana.410270519 · Cited by 138
Self-citationGiannini, C., Burger, P. C., Berkey, B. A., Cairncross, J. G., Jenkins, R. B., Mehta, M. P., Curran, W. J., & Aldape, K. D. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00129.x · Cited by 136
Self-citationPrevalence of BRCA1 Mutation Carriers among U.S. Non-Hispanic Whites
Whittemore, A. S., Gong, G. D., John, E. M., McGuire, V. M., Li, F. P., Ostrow, K. L., DiCioccio, R. A., Felberg, A., & West, D. W. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.2078.13.12 · Cited by 124
Erdem‐Eraslan, L., Gravendeel, L. A. M., de Rooi, J., Eilers, P. H. C., Idbaïh, A., Spliet, W. G. M., den Dunnen, W. F. A., Teepen, J. L. J. M., Wesseling, P., Smitt, P. A. E. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1444 · Cited by 110
van den Bent, M. J., Gravendeel, L. A. M., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., Teepen, J. L. J. M., Idbaïh, A., Sanson, M., Smitt, P. A. E. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1274 · Cited by 108
Moving toward molecular classification of diffuse gliomas in adults
Theeler, B. J., Yung, W. K. A., Fuller, G. N., & de Groot, J. (2012) · Neurology · doi:10.1212/wnl.0b013e318271f7cb · Cited by 90
Distinct germ line polymorphisms underlie glioma morphologic heterogeneity
Jenkins, R. B., Wrensch, M., Johnson, D. R., Fridley, B. L., Decker, P. A., Xiao, Y., Kollmeyer, T. M., Rynearson, A. L., Fink, S. R., Rice, T., et al. (2011) · Cancer Genetics · doi:10.1016/j.cancergencyto.2010.10.002 · Cited by 85
Self-citationDNA hypermethylation and 1p Loss silence NHE‐1 in oligodendroglioma
Blough, M. D., Al‐Najjar, M., Chesnelong, C., Binding, C., Rogers, A. D., Luchman, H. A., Kelly, J. J., Fliegel, L., Morozova, O., Yip, S. S. F., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23610 · Cited by 22
Self-citation
Cited by
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
Self-citationRadiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064
Self-citationTargeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“For example, tumors harboring an IDH mutation have increased sensitivity to hypomethylating agents (Turcan et al., 2013), electron transport chain inhibitors (Grassian et al., 2014), depletion of the coenzyme NAD+ (Tateishi et al., 2015) and chemoradiotherapy (Cairncross et al., 2014).”
BackgroundAdvances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
Metadata
- Authors
- Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., Huse, J. T., Mehta, M. P., & Curran, W. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-03-10
- Volume
- 32
- Issue
- 8
- Pages
- 783-790
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171074831
- Cited by
- 402
- References
- 50
- FWCI
- 23.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.